Nurse Practitioner, Family · Meridian, MS
NPI
1497241285
Since 2018
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1312 22nd Ave
Meridian, MS, 39301
Phone (601) 282-1424
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
2,182 services
Medicare patients, 2024
204
Average age 70
Drug cost, 2024
$1.6M
1,313 prescriptions
Company payments, 2025
$1,063
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James E Cooksey was code 99213 (office e&m - established), 656 times for 170 patients. In total James E Cooksey billed 2,182 services in 21 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-12-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 656 | 170 | $51.86 | $34K |
| 17003 Destruction Skin Lesion | Office | 477 | 65 | $3.41 | $1,624 |
| 96401 Chemotherapy Administration | Office | 259 | 29 | $39.04 | $10K |
| 96910 Skin | Office | 212 | 68 | $59.83 | $13K |
| 17000 Destruction Skin Lesion | Office | 127 | 68 | $33.67 | $4,276 |
| 99203 Office E&M - New | Office | 83 | 83 | $57.65 | $4,785 |
| 11102 Skin Biopsy | Office | 63 | 58 | $53.94 | $3,398 |
| 99214 Office E&M - Established | Office | 60 | 49 | $72.03 | $4,322 |
| 17250 Destruction Skin Lesion | Office | 47 | 32 | $45.42 | $2,135 |
| 11900 Skin | Office | 43 | 21 | $30.25 | $1,301 |
| 17004 Destruction Skin Lesion | Office | 42 | 25 | $94.18 | $3,956 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 42 | 21 | $0.75 | $31.31 |
| 17110 Destruction Skin Lesion | Office | 19 | 12 | $57.50 | $1,093 |
By year: 2022 $71K for 1,981 services; 2023 $93K for 2,234 services; 2024 $85K for 2,182 services.
Medicare prescription drug claims, 2024
In 2024, the drug James E Cooksey prescribed most often to Medicare patients was Triamcinolone Acetonide, with 205 prescriptions and refills. In total James E Cooksey wrote 1,313 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 205 | 209 | 86 | $3,190 |
| Ketoconazole Generic | 125 | 130 | 49 | $1,864 |
| Tacrolimus Generic | 114 | 114 | 50 | $12K |
| Betamethasone Valerate Generic | 98 | 98 | 37 | $4,064 |
| Dupixent Syringe Dupilumab | 82 | 82 | 12 | $328K |
| Dupixent Pen Dupilumab | 74 | 74 | 13 | $275K |
| Otezla Apremilast | 51 | 51 | Under 11 | $239K |
| Mupirocin Generic | 37 | 37 | 21 | $317 |
| Doxycycline Hyclate Generic | 32 | 34 | 17 | $326 |
| Adbry Tralokinumab-Ldrm | 31 | 33 | Under 11 | $119K |
| Clindamycin Phosphate Generic | 29 | 29 | 17 | $804 |
| Hydroxyzine Hcl Generic | 29 | 30 | Under 11 | $162 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 28 | 28 | 13 | $669 |
| Minocycline Hcl Generic | 28 | 32 | 14 | $367 |
| Pimecrolimus Generic | 26 | 29 | Under 11 | $5,570 |
Brand drugs: 447 claims; generic drugs: 866 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James E Cooksey $1,063 ($1,063 in general payments such as food, travel and fees) from 12 companies. The largest payer was Janssen Biotech, Inc. with $186.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 10 | $186 |
| Genzyme Corporation SNY | 6 | $178 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $165 |
| LEO Pharma Inc. | 11 | $139 |
| Abbvie Inc. ABBV | 5 | $116 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $105 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $55.21 |
| Arcutis Biotherapeutics, Inc. ARQT | 2 | $34.21 |
| Pfizer Inc. PFE | 1 | $28.61 |
| Lilly USA, LLC LLY | 1 | $24.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.